FY2024 Earnings Estimate for TSE:ONC Issued By HC Wainwright

Oncolytics Biotech Inc. (TSE:ONC) – Equities researchers at HC Wainwright reduced their FY2024 earnings estimates for Oncolytics Biotech in a research report issued on Wednesday, November 13th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of ($0.41) per share for the year, down from their prior estimate of ($0.39). The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Oncolytics Biotech’s Q3 2025 earnings at ($0.10) EPS.

Separately, Raymond James raised shares of Oncolytics Biotech to a “moderate buy” rating in a report on Thursday, November 14th.

Oncolytics Biotech Stock Up 0.7 %

ONC opened at C$1.39 on Monday. Oncolytics Biotech has a fifty-two week low of C$1.15 and a fifty-two week high of C$2.32. The company has a debt-to-equity ratio of 6.09, a quick ratio of 8.86 and a current ratio of 4.99. The company has a fifty day moving average of C$1.50 and a two-hundred day moving average of C$1.45. The stock has a market capitalization of C$106.84 million, a price-to-earnings ratio of -3.63 and a beta of 1.35.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.